Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study

Bartsch, Rupert; Wenzel, Catharina; Hussian, Dagmar; Pluschnig, Ursula; Sevelda, U.; Koestler, W.; Altorjai, Gabriela; Locker, Gottfried J.; Mader, Robert M.; Zielinski, Christoph; Steger, Guenther G.

doi:10.1186/1471-2407-6-63

Cited by 53 publications

(33 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[140][141][142] When used as a single treatment agent, trastuzumab increases the duration of survival, which is augmented by the administration of additional chemotherapeutic agents. 128,138,143 The most severe complication of trastuzumab therapy has been its potential to adversely affect cardiac function; however, the exact mechanism of its cardiotoxicity remains unclear.…”

Section: Targeted Biologic Therapies: Trastuzumab and Lapatinibmentioning

confidence: 99%

Breast Cancer Survivorship: A Comprehensive Review of Long-Term Medical Issues and Lifestyle Recommendations

Bodai¹,

Tuso

2015

TPJ

286

163

View full text Add to dashboard Cite

Section: Targeted Biologic Therapies: Trastuzumab and Lapatinibmentioning

confidence: 99%

Breast Cancer Survivorship: A Comprehensive Review of Long-Term Medical Issues and Lifestyle Recommendations

Bodai¹,

Tuso

2015

TPJ

286

163

View full text Add to dashboard Cite

“…Follow-up of patients who progressed on trastuzumab plus docetaxel in a phase II MBC trial reported a median postprogression survival time of 20 months for six patients who continued trastuzumab treatment beyond progression [52], and results from several retrospective analyses of case series also indicate that patients continue to derive benefit from trastuzumab after disease progression [53][54][55]. In a retrospective analysis of patients with HER-2-positive MBC, objective response rates and TTP were maintained in patients receiving two or more trastuzumab-based regimens (Table 2) [53].…”

Section: Trastuzumab Use Beyond Disease Progression In Mbcmentioning

confidence: 99%

“…In a retrospective analysis of patients with HER-2-positive MBC, objective response rates and TTP were maintained in patients receiving two or more trastuzumab-based regimens (Table 2) [53].…”

Section: Trastuzumab Use Beyond Disease Progression In Mbcmentioning

confidence: 99%

HER-2-Positive Metastatic Breast Cancer: Optimizing Trastuzumab-Based Therapy

Jackisch

2006

The Oncologist

View full text Add to dashboard Cite

Trastuzumab with a taxane as first-line therapy is now the standard of care for patients with human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer (MBC). The search for additional and more effective trastuzumab-based therapies continues. Novel combinations of trastuzumab with chemotherapeutic agents, including vinorelbine, gemcitabine, and capecitabine, and hormonal therapy agents, such as tamoxifen and aromatase inhibitors, are currently under investigation in clinical trials. Available data suggest these combinations will provide additional treatment options that may ultimately lead to better outcomes for patients with HER-2-positive MBC. Evidence is growing for the use of trastuzumab treatment beyond disease progression and retreatment after (neo)adjuvant relapse is being explored to assist in clinical decision making. Already, the use of trastuzumab in the metastatic setting has changed HER-2-positive status from a marker of poor prognosis to one of better overall outcome, and ongoing studies should expand further the treatment options for patients with HER-2-positive MBC.

show abstract

“…On the other hand, changing the traditional treatment paradigm in patients progressing on trastuzumab and administering further trastuzumab-based therapy beyond disease progression may have clinical benefit [65][66].This "treatment beyond progression" approach is increasingly being studied in clinical trials by combining trastuzumab either with chemotherapy [67][68] or with another targeted agent, such as the RTKI lapatinib [69]. Trastuzumab-DM1 (T-DM1) is an anti-HER-2 antibody drug conjugate comprising trastuzumab linked to the maytansine derivative DM1.…”

Section: Monoclonal Antibodiesmentioning

confidence: 99%